| Abnormality pattern of F-18 FDG PET whole body with functional MRI brain in post-acute COVID-19 P Kiatkittikul, C Promteangtrong, A Kunawudhi, D Siripongsatian, ... Nuclear Medicine and Molecular Imaging 56 (1), 29-41, 2022 | 19 | 2022 |
| Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines G Cohen, P Jungsomsri, J Sangwongwanich, K Tawinprai, ... Human Vaccines & Immunotherapeutics 18 (5), 2052525, 2022 | 16 | 2022 |
| Alterations in 18F-FDG PET/MRI and 15O-water PET brain findings in patients with neurological symptoms after COVID-19 vaccination: a pilot study D Siripongsatian, A Kunawudhi, C Promteangtrong, P Kiatkittikul, ... Clinical nuclear medicine 47 (3), e230-e239, 2022 | 14 | 2022 |
| Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population K Tawinprai, T Siripongboonsitti, T Porntharukchareon, B Dechates, ... Human Vaccines & Immunotherapeutics 18 (1), 2035573, 2022 | 14 | 2022 |
| Transmissibility of SARS-CoV-2 variants as a secondary attack in Thai households: a retrospective study N Watanapokasin, T Siripongboonsitti, T Ungtrakul, M Muadchimkaew, ... IJID regions 1, 1-2, 2021 | 13 | 2021 |
| Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers … K Tawinprai, T Siripongboonsitti, T Porntharukchareon, K Wittayasak, ... Vaccine 40 (12), 1761-1767, 2022 | 11 | 2022 |
| Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label … T Siripongboonsitti, T Ungtrakul, K Tawinprai, T Nimmol, M Buttakosa, ... International Journal of Infectious Diseases 134, 211-219, 2023 | 8 | 2023 |
| Safety and immunogenicity of the BBIBP-CorV vaccine in adolescents aged 12 to 17 years in the Thai population: an Immunobridging study K Tawinprai, T Siripongboonsitti, T Porntharukchareon, P Vanichsetakul, ... Vaccines 10 (5), 807, 2022 | 6 | 2022 |
| Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 … T Siripongboonsitti, N Nontawong, K Tawinprai, O Suptawiwat, ... Microbiology Spectrum 11 (6), e03257-23, 2023 | 4 | 2023 |
| Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study … T Siripongboonsitti, T Ungtrakul, K Tawinprai, C Auewarakul, ... Phytomedicine 119, 155018, 2023 | 4 | 2023 |
| Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV) T Siripongboonsitti, M Muadchimkaew, K Tawinprai, O Issaranon, ... Scientific Reports 13 (1), 14884, 2023 | 4 | 2023 |
| Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated … K Tawinprai, T Siripongboonsitti, T Porntharukchareon, K Wittayasak, ... Expert Review of Vaccines 21 (12), 1873-1881, 2022 | 4 | 2022 |
| Effect of inactivated SARS-CoV-2 vaccines and ChAdOx1 nCoV-19 vaccination to prevent COVID-19 in Thai households (VacPrevent trial) M Muadchimkaew, T Siripongboonsitti, S Wongpatcharawarakul, ... International Journal of Infectious Diseases 124, 190-198, 2022 | 4 | 2022 |
| The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study T Porntharukchareon, W Chartisathian, M Navinpipat, C Samdaengpan, ... Human Vaccines & Immunotherapeutics 19 (2), 2251850, 2023 | 3 | 2023 |
| Pharmacokinetic comparison of favipiravir oral solution and tablet formulations in healthy thai volunteers T Siripongboonsitti, T Ungtrakul, N Watanapokasin, P Timsri, ... Clinical Pharmacology in Drug Development 12 (1), 14-20, 2023 | 3 | 2023 |
| The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study N Nontawong, T Siripongboonsitti, K Tawinprai, M Boonpratoom, ... Annals of Clinical Microbiology and Antimicrobials 21 (1), 51, 2022 | 3 | 2022 |
| The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective … T Siripongboonsitti, K Tawinprai, K Cheirsilpa, T Ungtrakul, W Krisorakun, ... Medicina 59 (6), 1098, 2023 | 2 | 2023 |
| Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study K Tawinprai, P Jungsomsri, O Pinijnai, F Tavonvunchai, A Lievjaroen, ... Human Vaccines & Immunotherapeutics 19 (1), 2206360, 2023 | 1 | 2023 |
| Native Valve Endocarditis from Aspergillus flavus T Siripongboonsitti, O Dhissayakamol, O Putcharoen, G Suwanpimolkul J Infect Dis Antimicrob Agents 32, 151-61, 2015 | 1 | 2015 |
| Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle … T Siripongboonsitti, K Tawinprai, T Porntharukcharoen, S Sirisreetreerux, ... Journal of Infection and Public Health, 102471, 2024 | | 2024 |
